Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 44,160Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 11Revlimid

02 3Revlimid

03 1Revlimid - BMS

04 1Revlimid - Celgene

PharmaCompass

01

Brand Name : Revlimid

Lenalidomide

arrow
DIA 2025
Not Confirmed

02

Brand Name : Revlimid

Lenalidomide

arrow
DIA 2025
Not Confirmed

Brand Name : Revlimid

arrow
DIA 2025
Not Confirmed

Lenalidomide

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 77

2020 Revenue in Millions : 52

Growth (%) : 48

blank

03

Brand Name : Revlimid

Lenalidomide

arrow
DIA 2025
Not Confirmed

04

Brand Name : Revlimid

Lenalidomide

arrow
DIA 2025
Not Confirmed

05

Brand Name : Revlimid

Lenalidomide

arrow
DIA 2025
Not Confirmed

06

Brand Name : Revlimid

Lenalidomide

arrow
DIA 2025
Not Confirmed

Brand Name : Revlimid

arrow
DIA 2025
Not Confirmed

Lenalidomide

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 82

2022 Revenue in Millions : 83

Growth (%) : -4

blank

07

Brand Name : Revlimid

Lenalidomide

arrow
DIA 2025
Not Confirmed

08

Brand Name : Revlimid

Lenalidomide

arrow
DIA 2025
Not Confirmed

Brand Name : Revlimid

arrow
DIA 2025
Not Confirmed

Lenalidomide

Main Therapeutic Indication : Oncology

Currency : USD

2024 Revenue in Millions : 36

2023 Revenue in Millions : 76

Growth (%) : -53

blank

09

Brand Name : Revlimid

Lenalidomide

arrow
DIA 2025
Not Confirmed

10

Brand Name : Revlimid

Lenalidomide

arrow
DIA 2025
Not Confirmed

Brand Name : Revlimid

arrow
DIA 2025
Not Confirmed

Lenalidomide

Main Therapeutic Indication : Blood Related Disorders

Currency : USD

2015 Revenue in Millions : 4,980

2014 Revenue in Millions : 5,801

Growth (%) : 16%

blank